Publications
![](https://march.bio/wp-content/uploads/2024/04/clinical-trial-2-1024x576.webp)
March 28, 2024
Phase 1 trial shows autologous CD5.CAR T cells are safe and effective in r/r T-cell lymphoma with a 44% overall response rate, promising advances in T-cell malignancy treatment.
![](https://march.bio/wp-content/uploads/2023/06/female-lab-tech-takes-sample-from-test-tube-to-res-2022-01-19-00-01-33-utc-1024x683.jpg)
June 2, 2023
We describe improved responses in T-ALL patients during a Phase I dose study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) following the addition of tyrosine kinase inhibitors during manufacturing.
![](https://march.bio/wp-content/uploads/2023/06/female-lab-tech-takes-sample-from-test-tube-to-res-2022-01-19-00-01-33-utc-1024x683.jpg)
November 13, 2019
We describe a Phase I dose escalation study (NCT03081910) of autologous CD5-directed chimeric antigen receptor T cell (CD5 CAR T) therapy for relapsed or refractory (r/r) T-cell leukemia and lymphoma.
News
![](https://march.bio/wp-content/uploads/2024/02/1440x0-1024x683.webp)
February 22, 2024
Cell therapy developed by Baylor scientists shows promise as woman remains cancer-free after 5 years
A CAR T cell therapy for T cell lymphoma showed promise in a Phase I clinical trial, Baylor College of Medicine scientists said.
![](https://march.bio/wp-content/uploads/2023/11/cprit.jpeg)
November 17, 2023
March Biosciences Awarded $13.4 Million by CPRIT to Advance Its CD5 CAR-T Therapy for T-cell Lymphoma in Phase 2 Trials
March Biosciences received a $13.4 million grant award from CPRIT to support continued clinical development of MB-105 CD5 CAR-T for T-cell lymphoma
![](https://march.bio/wp-content/uploads/2023/11/500_houstoninnologo845x.jpg)
November 9, 2023
Cancer Focus Fund invests $4.8M into Houston-based March Biosciences
The Cancer Focus Fund LP invested $4.8 million into a cell therapy company that has already tapped some of Houston’s growing life sciences resources.
All News Loaded